<DOC>
	<DOC>NCT02008539</DOC>
	<brief_summary>To evaluate the safety and tolerability of MSC_apceth_101.</brief_summary>
	<brief_title>Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<criteria>Patients with advanced or recurrent or metastatic gastrointestinal adenocarcinoma. Premature or scheduled termination of standard therapy Progressive disease as clinically assessed by the investigator Max. tumour lesion ≤ 5 cm Adequate organ function Ability of patient to understand character and individual consequences of clinical trial Age ≥ 18 years Written informed consent must be available before any study specific procedure is performed Patients with severe heart diseases Clinical significant ischemic disease during the last 4 weeks before Visit 1 Severe lung disease Symptomatic peritoneal carcinomatosis Symptomatic pleural or pericardial effusion Serious uncontrolled acute infections less than 3 weeks before Visit 1 Known dependency on alcohol or other drugs Patients requiring corticoids in doses above the Cushing threshold Known liver fibrosis or liver cirrhosis Any concomitant severe disease which could compromise the objectives of this study in the judgment of the investigator Female patient who is pregnant or breast feeding Participation in another clinical trial or observation period, respectively, during the last 4 weeks prior to the first IMP dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>